Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 467

Similar articles for PubMed (Select 17668560)

1.

Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE.

Antivir Ther. 2007;12(4):515-21.

PMID:
17668560
2.

Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.

Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, Audu RA, Araoyinbo ID, Onyewuche JI, Salu OB, Adedoyin JA, Musa AZ.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-9.

PMID:
16123684
3.

Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.

Manosuthi W, Tantanathip P, Prasithisirikul W, Likanonsakul S, Sungkanuparph S.

BMC Infect Dis. 2008 Oct 14;8:136. doi: 10.1186/1471-2334-8-136.

4.

Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.

Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S.

Clin Infect Dis. 2007 Jan 1;44(1):141-4. Epub 2006 Nov 21.

5.

Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.

Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D, Ruxrungtham K.

Antivir Ther. 2008;13(4):529-36.

PMID:
18672531
6.

Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India.

Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, Mane AA, Bhagat S.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1566-9.

PMID:
15577409
7.

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.

Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E.

Lancet. 2004 Jul 3-9;364(9428):29-34.

PMID:
15234853
8.

Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.

Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F; VIRGO Study Team.

Antivir Ther. 1999;4 Suppl 3:83-4.

PMID:
16021876
9.

Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi?

Zachariah R, Teck R, Ascurra O, Gomani P, Manzi M, Humblet P, Nunn P, Salaniponi FM, Harries AD.

Int J Tuberc Lung Dis. 2005 Mar;9(3):238-47. Review.

PMID:
15786885
10.

Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?

Chang SY, Lin SW, Hung CC.

Clin Infect Dis. 2009 Nov 1;49(9):1452-3; author reply 1453-4. doi: 10.1086/644494. No abstract available.

11.

Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.

Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P.

J Med Assoc Thai. 2006 Sep;89(9):1472-8.

PMID:
17100387
12.
13.

Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.

Antivir Ther. 2004 Apr;9(2):197-204.

PMID:
15134181
14.

Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.

Matteelli A, Saleri N, Villani P, Bonkoungou V, Carvalho AC, Kouanda S, Sanou MJ, Simporé J, Monno L, Carosi G, Regazzi M, Dembele M.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):64-9.

PMID:
19731452
15.

Management of individuals requiring antiretroviral therapy and TB treatment.

Cohen K, Meintjes G.

Curr Opin HIV AIDS. 2010 Jan;5(1):61-9. doi: 10.1097/COH.0b013e3283339309. Review.

16.

Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.

Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V.

Pediatr Infect Dis J. 2009 Mar;28(3):246-8. doi: 10.1097/INF.0b013e31818dd72b.

PMID:
19165130
17.

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.

Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM; ALBI (ANRS 070) Study Group.

Antivir Ther. 1999;4 Suppl 3:71-4.

PMID:
16021874
18.

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.

Maartens G, Decloedt E, Cohen K.

Antivir Ther. 2009;14(8):1039-43. doi: 10.3851/IMP1455. Review.

PMID:
20032533
19.

Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US.

Eur J Clin Pharmacol. 2009 Jan;65(1):71-80. doi: 10.1007/s00228-008-0481-y. Epub 2008 Aug 27.

PMID:
18751690
20.

Tuberculosis and HIV co-infection: a practical therapeutic approach.

Breen RA, Swaden L, Ballinger J, Lipman MC.

Drugs. 2006;66(18):2299-308. Review.

PMID:
17181373
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk